Kura Oncology
Market cap $688M 91.9M shares (10-Q, Nov 6, 2026) × $7.49 close Nov 17, 2026
Most recent annual filing: 2026-03-05
- ziftomenib (KOMET-008) / darlifarnib +2H 2026ziftomenib (KOMET-008) / darlifarnib +, 2H 2026, notable
- ziftomenib Ph3 topline2028ziftomenib Ph3 topline, 2028, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (13 active programs)
darlifarnib
- Renal Cell Carcinoma
- Undisclosed indication
- Salivary Gland Cancer
darlifarnib
KO-2806KO-7246
- Undisclosed indication
- Type 1 Diabetes
- Type 2 Diabetes
Discontinued (1)
- tipifarnib — Head and Neck Squamous Cell Carcinoma · KURRENT-HN trial completed in Q3 2025; evaluating data generation options for next steps with darlifarnib combination
Capital (as filed)
- Cash
- $57.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $434M Sep 30, 2026
- Operating cash flow
- −$54.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $492M cash, runway into 2028 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (8)
- 2026-11-11 UPDATE: Kura Oncology (KURA) - The Barometer Moved 🔒 Paid
- 2026-09-09 UPDATE: Kura Oncology (KURA) - The Diabetes Option Gets Its Own Balance Sheet 🔒 Paid
- 2026-08-13 UPDATE: Kura Oncology (KURA) - The Launch Wins the Head-to-Head 🔒 Paid
- 2026-07-28 UPDATE: Kura Oncology (KURA) - The Call Option Grows Teeth 🔒 Paid
- 2026-06-11 UPDATE: Kura Oncology (KURA) — The Binary Prints, Three Days Early 🔒 Paid
- 2026-06-02 UPDATE: Kura Oncology (KURA) — The Ven/Aza Arm Gets Its Receipt 🔒 Paid
- 2026-05-30 UPDATE: Kura Oncology (KURA) — Subscriber Update
- 2026-05-15 Kura Oncology (KURA) - Scientific Deep Dive for Ziftomenib and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (8 calls)
Every verdict Biotech Distilled has published on Kura Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-15 Buy core Kura Oncology (KURA) - Scientific Deep Dive for Ziftomenib and Pipeline Products Kura is a fundamentally de-risked biotech with a commercially approved, differentiated NCE, cash runway past major Phase 3 readouts, and a massive embedded call option in frontline AML combination trials targeting a ~$7B TAM.
- 2026-05-30 Buy core UPDATE: Kura Oncology (KURA) — Subscriber Update Darlifarnib Phase 1a data printed green as proof-of-mechanism across KRAS inhibitors, but the thesis spine is unchanged — KURA remains a ziftomenib/AML story with the real binary at EHA on June 14.
- 2026-06-02 Buy core UPDATE: Kura Oncology (KURA) — The Ven/Aza Arm Gets Its Receipt Peer-reviewed Blood publication confirms 75% central MRD-negativity and clean safety for the ven/aza combination arm, materially de-risking the KOMET-017-NIC frontline thesis ahead of the June 14 EHA binary.
- 2026-06-11 Buy core UPDATE: Kura Oncology (KURA) — The Binary Prints, Three Days Early KOMET-007 posted 94% 12-month OS in NPM1-m and 71% in KMT2A-r with zero Grade 4 DS or QTc events, clearing the highest-stakes catalyst between now and the 2028 KOMET-017 topline and validating the frontline backbone thesis.
- 2026-07-28 Buy core UPDATE: Kura Oncology (KURA) - The Call Option Grows Teeth Darlifarnib posted 33–50% ORR and 13-month median PFS in pre-treated ccRCC with a randomized Phase 1b now running for Phase 3 dose selection, thickening the call option without altering the AML core valuation.
- 2026-08-13 Buy core UPDATE: Kura Oncology (KURA) - The Launch Wins the Head-to-Head Q2 KOMZIFTI revenue of $9.1M (+57% QoQ) and majority share of new patient starts in the R/R NPM1-m menin inhibitor class validates the differentiated-safety commercial thesis, firming the floor under the 2028 frontline binary.
- 2026-09-09 Buy core UPDATE: Kura Oncology (KURA) - The Diabetes Option Gets Its Own Balance Sheet Kura spun KO-7246 into Caspian Therapeutics with $50M of external capital at zero cost to existing holders, creating optionality in a massive diabetes TAM while the AML spine and 2028 KOMET-017 binary remain unchanged.
- 2026-11-11 Buy core UPDATE: Kura Oncology (KURA) - The Barometer Moved Q3 revenue compounded to $13.9M (+53% QoQ) with majority class share maintained, but the ATM was tapped at $12.64 and a new $150M ATM now sits over a $7.57 stock alongside Oberland secured debt, requiring dilution monitoring while the clinical spine remains intact.
- Long call · opened May 15, 2026 at $9.22 · -18.8% vs XBI +11.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Complete enrollment in the randomized FIT-001 Phase 1b study evaluating darlifarnib plus cabozantinib in cabozantinib-naïve ccRCC in 1H 2027 and report initial clinical data in 2H 2027”
matched to ziftomenib (KOMET-017) · topline data
-
-
-
“We expect to complete enrollment in the FIT-001 Phase 1b study evaluating darlifarnib plus cabozantinib in cabozantinib-naïve ccRCC in the first half of 2027 and to report initial clinical data in the second half of 2027.”
matched to darlifarnib + adagrasib · interim data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (35)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 26, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 2026ReleaseKura Oncology to Participate in Two Investor Conferences in November
- Nov 10, 2026S-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- Nov 10, 2026ReleaseKura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateKURA's Q3 earnings arrived with a 53% sequential revenue beat and majority class share intact — but the stock has cratered 37% since my last update, and a new Oberland debt deal carrying a royalty participation on KOMZIFTI sales changes the financial picture materially. Here's what changed and what it means for the thesis.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseKura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
- Nov 3, 2026ReleaseKura Oncology to Report Third Quarter Financial Results on November 10
- Oct 13, 2026ReleaseCaspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesBD extracted 1 program update from this document → KURA pipeline
- Oct 7, 2026ReleaseCaspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
- Sep 29, 2026ReleaseCaspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
- Sep 9, 2026ReleaseKura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes→ BD updateSummary on the 8-KBD extracted 1 program update from this document → KURA pipeline
- Sep 9, 20268-KCurrent report: other events→ BD updateKura just spun out Caspian Therapeutics with $50M in external financing to advance KO-7246 — the menin inhibitor diabetes program I called a discovery-stage call option in the deep dive — leaving KURA's oncology cash runway completely intact while unlocking a separately capitalized shot at a disease-modifying diabetes approach.
- Sep 8, 2026ReleaseKura Oncology Appoints Jennifer Fulk as Chief Financial Officer
- Sep 8, 20268-KCurrent report: officer / director change
- Sep 1, 2026ReleaseKura Oncology to Participate in Three Investor Conferences in September
- Aug 12, 2026ReleaseKura Oncology Reports Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → KURA pipeline
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1
- Aug 12, 202610-QQuarterly reportBD extracted 1 program update from this document → KURA pipeline
- Aug 10, 2026ReleaseKura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
- Aug 5, 2026ReleaseKura Oncology to Report Second Quarter Financial Results
- Jul 29, 20268-KCurrent report: officer / director change
- Jul 27, 2026ReleaseKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026BD extracted 1 program update from this document → KURA pipeline
- Jul 14, 2026ReleaseKura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026BD extracted 1 program update from this document → KURA pipeline
- Jun 11, 2026ReleaseKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLBD extracted 1 program update from this document → KURA pipeline
- Jun 4, 20268-KCurrent report: officer / director change, shareholder vote · EX-99.1
- Jun 3, 2026ReleaseKura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development StrategyBD extracted 2 program updates from this document → KURA pipeline
- Jun 2, 2026ReleaseKura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AMLBD extracted 1 program update from this document → KURA pipeline
- May 26, 2026ReleaseKura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
- May 26, 2026DEFA14AProxy soliciting material
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 10, 2026DEFA14AProxy soliciting material
- Apr 10, 2026DEF 14AProxy statement
- Mar 5, 20268-KCurrent report: results of operations · EX-99.1
- Mar 5, 202610-KAnnual report
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Oct 27, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jun 4, 2026S-8Employee plan registration
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 10, 2026ARSAnnual report to shareholders
- Mar 27, 2026SCHEDULE 13G/A13G amendment